Skip to main content
Log in

QT-Interval prolonging drugs: Mechanisms and clinical relevance of their arrhythmogenic hazards

  • Forum on Torsades de Pointes Part Three
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

The antiarrhythmic principle of drug-induced QT-interval prolongation is well known. However, with the widespread use of the presently known and new Class III antiarrhythmic agents under investigation, and the growing number of agents not primarily designed as antiarrhythmic drugs that potentially cause QT prolongation, we have also become aware of the proarrhythmic hazards associated with many of these agents. The proarrhythmic risk differs markedly from one agent to another and interferes with many individual clinical variables (e.g., hypokalemia, sinus bradycardia). This paper summarizes the present data on the proarrhythmic risk of drug-induced QT prolongation, including the value and problems of the rate-corrected QT interval, the mechanisms involved in the genesis of proarrhythmia, and the clinical cofactors that facilitate the occurrence of proarrhythmic events. In addition, an extensive database provides information on the known proarrhythmic risk of all currently used QT-prolonging agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abildskov JA. Effects of activation sequence on local recovery of ventricular excitability in the dog.Circ Res 1976; 38:240–426.

    PubMed  CAS  Google Scholar 

  2. Abildskov JA. The ventricular gradient and repolarization.Jpn Heart J 1986;27:197–204.

    PubMed  Google Scholar 

  3. Abrahamsson C, Almgren O. Autonomic control of ventricular repolarization and refractoriness in conscious dogs. In: Butrous GS, Schwartz P, eds.Clinical aspects of ventricular repolarization. London: Farrand Press, 1989:131.

    Google Scholar 

  4. Ahnve S. Methodological aspects of QTc interval determination. In: Butrous GS, Schwartz PJ, eds.Clinical aspects of ventricular repolarization. London: Farrand Press, 1989:1–17.

    Google Scholar 

  5. Ahnve S. Errors in the visual determination of corrected QT (QTc) interval during acute myocardial infarction.J Am Coll Cardiol 1985;5:699–702.

    PubMed  CAS  Google Scholar 

  6. Altura BM, Altura BT. New perspectives on the role of magnesium in the pathophysiology of the cardiovascular system.Magnesium 1985;4:226–244.

    PubMed  CAS  Google Scholar 

  7. Arena JP, Kass RS. Block of heart potassium channels by clofilium and its teritary analogs: Relationship between drug structure and type of channel blocked.Mol Pharmacol 1988;34:60–66.

    PubMed  CAS  Google Scholar 

  8. Baumann JL, Pharm D, Bauernfeind RA, et al. Torsade de pointes due to quinidine: Observations in 31 patients.Am Heart J 1984;107:425–430.

    Article  Google Scholar 

  9. Bayer R, Rodenkirchen R, Kaufman R, et al. The effects of nifedipine on contraction and monophasic action potentials of isolated cat ventricular myocardium.Naunyn Schmiedebergs Arch Pharmacol 1977;301:29–37.

    Article  PubMed  CAS  Google Scholar 

  10. Bazett HC. An analysis of the time-relations of electrocardiograms.Heart 1920;7:353–370.

    Google Scholar 

  11. Belton P, Sheridan J, Mulcahy R. A case of sotalol poisoning.Ir J Med Sci 1982;151:126–127.

    Article  PubMed  CAS  Google Scholar 

  12. Bennet JM, Gourassas J, Konstantinides S. Torsade de pointes induced by sotalol and hypokalemia.S Afr Med J 1985;68:591–592.

    Google Scholar 

  13. Bens JL, Duboisset M, Quiret JC, et al. Syncopes par torsades de pointes.Nouv Press Med 1979;2:165–166.

    Google Scholar 

  14. Bhandari AK, Scheinman M. Torsade de pointes: Is the term necessary? In: Butrous GS, Schwartz P, eds.Clinical aspects of ventricular repolarization. London: Farrand Press, 1989:305.

    Google Scholar 

  15. Binah O, Rubinstein I, Gilat E. Effects of thyroid hormone and the action potential and membrane currents of guinea pig ventricular myocytes.Pflügers Arch 1987;409:214–216.

    Article  PubMed  CAS  Google Scholar 

  16. Blanloeil Y, Pinaud M, Nicolas F. Torsades de pointe après injection de suxaméthonium chez deux coronariens digitalisés.Nouvelle Presse Méd 1979;21(8):1765.

    Google Scholar 

  17. Bonatti V, Rolli A, Finardi A, Botti G. Mechanisms and clinical relevance of QT prolongation and related arrhythmias. In: Butrous GS, Schwartz P, eds.Clinical aspects of ventricular repolarization. London: Farrand Press, 1989: 257–271.

    Google Scholar 

  18. Brachmann J, Scherlag BJ, Rosenshtraukh LV. Bradycardia-dependent triggered activity. Relevance to drug-induced multiform ventricular tachycardia.Circulation 1983;68:846–856.

    PubMed  CAS  Google Scholar 

  19. Breithardt G, Seipel L, Haerten K. Paradoxe reaktion nach disopyramid und chinidin.Z Kardiol 1980;69:556–561.

    PubMed  CAS  Google Scholar 

  20. Brochier M, Fauchier JP. Torsades de pointe et rentrées provoquées par les antiarythmiques.Arch Mal Coeur 1978; 71:477–488.

    PubMed  CAS  Google Scholar 

  21. Brown AM, Cade JF. Cardiac arrhythmias after chloral hydrate overdose.Med J Aust 1980;1:28–29.

    PubMed  CAS  Google Scholar 

  22. Butrous GS, Butrous MS, Camm AJ. Dynamic interactions between heart rate and autonomie neural activities on the QT interval. In: Butrous GS, Schwartz P, eds.Clinical aspects of ventricular repolarization. London: Farrand Press, 1989:139–151.

    Google Scholar 

  23. Butrous GS, Schwartz P.Clinical aspects of ventricular repolarization. London: Farrand Press, 1989.

    Google Scholar 

  24. Campbell TJ. Subclassification of class Ia antiarrhythmic drugs. In: Vaughan Williams, EM, ed.Antiarrhythmic drugs. Springer Verlag, 1989:135.

  25. Campbell TJ. Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle and provide a theoretical basis for their subclassification.Cardiovasc Res 1983;17:344–352.

    Article  PubMed  CAS  Google Scholar 

  26. Campbell TJ, Vaughan Williams EM. Voltage and timedependent depression of maximum rate of depolarization of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, flecainide and lorcainide. 1983;17: 251–258.

    CAS  Google Scholar 

  27. Cardiac Arrhythmia Suppression Trial (CAST) investigators. Preliminary report: Effects of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.N Engl J Med 1989;321: 406–412.

    Google Scholar 

  28. Carmeliet E. Electrophysiologic and voltage clamp analysis of sotalol effects in cardiac muscle and Purkinje fibers.J Pharmacol Ther 1985;232:817–825.

    CAS  Google Scholar 

  29. Carmeliet E. Electrophysiological effects of encainide on isolated cardiac muscle and Purkinje fibers and on the Langendorff perfused guinea pig heart.Eur J Pharmacol 1980;61:247–262.

    Article  PubMed  CAS  Google Scholar 

  30. Casedevant B, Sabaut D, Clementy J, Dallochio M. Syncopes par tordasades de pointes en rapport avec la prise de Disopyramide.Nouv Presse Med 1975;4:2339.

    PubMed  CAS  Google Scholar 

  31. Castellanos A, Salhanick L. Electrocardiographic pattern of procainamide cardiotoxicity.Am J Med Sci 1967;253: 52–57.

    Article  PubMed  Google Scholar 

  32. Clark M, Friday K, Anderson J. Drug induced torsade de pointes: High concordance rate among type IA antiarrhythmic drugs and amiodarone.J Am Coll Cardiol 1985;5:450.

    Google Scholar 

  33. Cobbe SM. Sotalol. In: Vaughan Williams, EM, ed.Antiarrhythmic drugs. Springer Verlag, 1989:365.

  34. Cohn JN. Symposium on bepridil, a new antianginal agent.Am J Cardiol 1985;55:1c-62c.

    Article  Google Scholar 

  35. Cokkinos DV, Tolis G, Koroxenidis G, Vorides EM. “Torsades de pointes” in variant angina successful treatment with verapamil.Acta Cardiol 1981;36(6):445–450.

    PubMed  CAS  Google Scholar 

  36. Colatsky TJ, Follmer CH. K channel blockers and activators in cardiac arrhythmias.Cardiovasc Drug Rev 1989;7:199–209.

    Article  Google Scholar 

  37. Conn HO, Ramsby GR, Storer EH. Selective intraarterial vasopressin in the treatment of upper gastrointestinal hemorrhage.Gastroenterology 1972;63:634–645.

    PubMed  CAS  Google Scholar 

  38. Coraboeuf E, Deroubaix E. Shortening effect of tetrodotoxin on action potentials of the conduction system in the dog heart.J Physiol 1978;280:24.

    Google Scholar 

  39. Coraboeuf E, Deroubaix E, Coulombe A. Effect of tetrodotoxin on action potentials of the conducting system in the dog heart.Am J Physiol 1979;236:H561-H567.

    PubMed  CAS  Google Scholar 

  40. Coumel P. The fuzzy set of long QT interval, torsade de pointes and the autonomie nervous system. In: Butrous GS, Schwartz P, eds.Clinical aspects of ventricular repolarization. London: Farrand Press, 1989:311.

    Google Scholar 

  41. Coumel P, Leclercq JF, Rosengarten M, et al. Unusual forms of severe ventricular tachyarrhythmias: Their relationships with the QT interval and the vago-sympathetic balance. In: Kulbertus HE Wellens JJ, ed.Sudden death. The Hague: Martinus Nijhoff Publishers, 1989:199.

    Google Scholar 

  42. Craft TM. Torsade de pointes after astemizole overdose.Br Med J 1986;292:660–668.

    CAS  Google Scholar 

  43. Cranefield PF. Action potentials, afterpotentials and arrhythmias.Circ Res 1977;41:415–423.

    PubMed  CAS  Google Scholar 

  44. Cripps T. The QT interval and its relationship to heart rate in patients after acute myocardial infarction. In: Butrous GS, Schwartz PJ, eds.Clinical aspects of ventricular repolarization. London: Farrand Press, 1989:369–379.

    Google Scholar 

  45. Czerny J, Dvozak K, Jurek F. Treatment of supraventricular cardiac arrhythmia with lidoflazine in intensive care unit and its short and long term results. In:Proceedings of the Second International Lidoflazine Symposium, Hamburg, FRB, 1975.

  46. Danilo P, Hordorf AJ, Rosen JR. Effects of disopyramide on electrophysiologic properties of canine cardiac Purkinje fibers.J Pharmacol Exp Ther 1977;201:701–710.

    PubMed  CAS  Google Scholar 

  47. Dany F, Liozon F, Goudoud JC, et al. Torsade de pointes et arythmies ventriculaires graves par administration parenterale de vincamine.Arch Mal Coeur 1979;73:298–306.

    Google Scholar 

  48. Davison ET. Amitriptyline-induced torsade de pointes, successful therapy with atrial pacing.J Electrocardiol 1985;18:299–301.

    Article  PubMed  CAS  Google Scholar 

  49. Denes P, Gabster A, Huang SK. Clinical, electrocardiographic and follow-up observations in patients having ventricular fibrillation during Holter monitoring. Role of quinidine therapy.Am J Cardiol 1981;48:9–16.

    Article  PubMed  CAS  Google Scholar 

  50. Denker S, Lehmann M, Mahmud R, et al. Facilitation of ventricular tachycardia induction with abrupt changes in ventricular cycle length.Am J Cardiol 1984;53:508–515.

    Article  PubMed  CAS  Google Scholar 

  51. Desautels S, Filteau C, SF-Jean A. Ventricular tachycardia associated with administration of thioridazine hydrochloride (Mellaril): Report of a case with a favourable outcome.Can Med Ass J 1964;90:1030–1036.

    PubMed  CAS  Google Scholar 

  52. Deveze JL, Sainty JM, David J. Intoxication volontaire au Fenoxedil.Nouv Presse Med 1976;5:23.

    Google Scholar 

  53. Dibble JB, Webster NR. Adverse reaction to disopyramide.Postgrad Med J 1979;55:570–572.

    Article  PubMed  CAS  Google Scholar 

  54. Duff HJ, Roden DM, Brorson L, et al. Electrophysiologic actions of high plasma concentrations of propranolol in human subjects.J Am Coll Cardiol 1983;2:1134–1140.

    PubMed  CAS  Google Scholar 

  55. Dyckner F, Wester PO. Ventricular extrasystoles and intracellular electrolytes before and after potassium and magnesium infusions in patients on diuretic treatment.Am Heart J 1979;97(1):12–18.

    Article  PubMed  CAS  Google Scholar 

  56. Echt DS, Bert LE, Clusin WT, et al. Prolongation of the human cardiac monophasic action potential by sotalol.Am J Cardiol 1982;50:1082–1086.

    Article  PubMed  CAS  Google Scholar 

  57. Echt DS, Kopelman HA, Lee TJ, et al. Control mechanisms for QT interval in man.Circulation 1986; 11:401.

    Google Scholar 

  58. Flammang D, Waynberger M, Jansen FH, et al. Electrophysiologic profile of bepridil, a new anti-anginal drug with calcium blocking properties.Eur Heart J 1983;4:647–654.

    Google Scholar 

  59. Follmer CH, Colatsky TJ. Block of delayed rectifier potassium current, Ik, by flecainide and E-4031 in cat ventricular myocytes.Circulation 1990;82:289–293.

    PubMed  CAS  Google Scholar 

  60. Forfar JC, Gribbin B. Torsade de pointes after amiodarone withdrawal; effects of mild hypokalemia on repolarization.Eur Heart J 1984;5:510–512.

    PubMed  CAS  Google Scholar 

  61. Fowler NO, McCall D, Chou T, et al. Electrocardiographs changes and cardiac arrhythmias in patients receiving psychotropic drugs.Am J Cardiol 1976;37:223–230.

    Article  PubMed  CAS  Google Scholar 

  62. Fredlund BD, Olsson SB. Long QT interval and ventricular tachycardia of “torsade de pointes” type in hypothyroidism.Acta Med Scand 1980;213:213–217.

    Google Scholar 

  63. Freeberg AS, Papp GJ, Vaughan Williams EM. The effects of altered thyroid state on atrial intracellular potentials.J Physiol 1970;207:357–369.

    Google Scholar 

  64. Frey W. Weitere erfahrungen mit chinidin bei absoluter herzunregelmäβigkeit.Wien Klin Wschr 1918;55:849–853.

    Google Scholar 

  65. Freyland MD, Steffel D, Hilger HH. Klinische erfahrungen mit dem neuen antiarrhythmikum aprindin an hand von langzeit-trendanalyse.Dtsch Med Wochenschr 1975; 36:1764–1767.

    Article  Google Scholar 

  66. Friedman H.Diagnostic electrocardiography and vectorcardiography. McGraw-Hill, 1977;78.

  67. Frisch C.Heart disease—A textbook of cardiovascular medicine. Philadelphia: W.B. Saunders, 1984:203.

    Google Scholar 

  68. Gascho JA, Schieken R. Congenital complete heart block and long Q-T syndrome requiring ventricular pacing for control of refractory ventricular tachycardia and fibrillation.J Electrocardiol 1979;12:331–335.

    Article  PubMed  CAS  Google Scholar 

  69. Gavrilescu S, Luca C. Right ventricular monophasic action potentials in patients with long QT syndrome.Br Heart J 1978;40:1014–1018.

    Article  PubMed  CAS  Google Scholar 

  70. Giles TD, Modlin RK. Death associated with ventricular arrhythmia and thioridazine hydrochloride.JAMA 1968; 205:108–112.

    Article  PubMed  CAS  Google Scholar 

  71. Gomes JAC, Kang PS, Hariman RJ, et al. Electrophysiologic effects and mechanisms of termination of supraventricular tachycardia by intravenous amiodarone.Am Heart J 1984;107:214–221.

    Article  PubMed  CAS  Google Scholar 

  72. Graboys TB, Podrid PJ Lown B. Efficacy of amiodarone for refractory supraventricular tachyarrhythmias.Am Heart J 1983;106:870–876.

    Article  PubMed  CAS  Google Scholar 

  73. Grenadier E, Alpan G, Kleidar S, Palant A. Atrioventricular block after administration of lignocaine in patients treated with prenylamine.Postgrad Med J 1982;58: 175–177.

    Article  PubMed  CAS  Google Scholar 

  74. Gustafson A, Svensson SE, Ugander L. Cardiac arrhythmias in chloral hydrate poisoning.Acta Med Scand 1977; 201:227–230.

    PubMed  CAS  Google Scholar 

  75. Hai H, Sato F. The high incidence of quinidine-induced aggravation of ventricular arrhythmias. At low therapeutic blood levels.Circulation 1987;57(Suppl II):435.

    Google Scholar 

  76. Harron DWG, Shanks RG. Clinical use of class Ib antiarrhythmic drugs. In: Vaughan Williams, EM, ed.Antiarrhythmic drugs. Springer Verlag, 1989:201.

  77. Haynes RE, Hallstrom HP, Cobb LA. Repolarization abnormalities in survivors of out-of-hospital ventricular fibrillation.Circulation 1978;57:654–658.

    PubMed  CAS  Google Scholar 

  78. Heger JJ, Prystowsky EN, Jackman WN, et al. Amiodarone: Clinical efficacy and electrophysiology during long term therapy for recurrent ventricular tachycardia or ventricular fibrillation.N Engl J Med 1981;305:539–545.

    PubMed  CAS  Google Scholar 

  79. Heidbuchel H, Callewaert G, Vereecke J, Carmeliet E. ATP-dependent activation of atrial muscarinic K channels in the absence of agonist and G-nucleotides.Pflügers Arch 1990;416:213–215.

    Article  PubMed  CAS  Google Scholar 

  80. Heidbuchel H, Vereecke J, Carmeliet E. Three different potassium channels in human atrium. Contribution of the basal conductance.Circ Res 1990;66(5):1277–1286.

    PubMed  CAS  Google Scholar 

  81. Heins J, Heinrich-Meisner G, Hennersdorf G, Harmjanz D. Kammerflattern bei suizidaler lidoflazin-intoxikation (Clinium® [Fa. Janssen]).Intensivmed 1977;14:309–312.

    Google Scholar 

  82. Henning B, Wit AL. The time course of action potential repolarization affects delayed afterdepolarization amplitude in atrial fibers of the canine coronary sinus.Circ Res 1984;55:110–115.

    PubMed  CAS  Google Scholar 

  83. Herrmann HC, Kaplan LM, Bierer BE. Q-T prolongation and torsades de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline.Am J Cardiol 1983;51:904–906.

    Article  PubMed  CAS  Google Scholar 

  84. Hodess AB, Follansbee WP, Spear JF, Moore EN. Electrophysiological effects of a new antiarrhythmic agent, flecainide, on the intact canine heart.J Cardiovasc Pharmacol 1979;1:427–439.

    Article  PubMed  CAS  Google Scholar 

  85. Hoffman BF, Rosen JR, Wit AL. Electrophysiology and pharmacology of cardiac arrhythmias. VII. Cardiac effects of quinidine and procainamide.Am Heart J 1975;89:804–809.

    Article  PubMed  CAS  Google Scholar 

  86. Hohnloser SH, Raeder EA, Podrid PJ, et al. Predictors of antiarrhythmic efficacy in patients with malignant ventricular tachyarrhythmias.Am Heart J 1987;114:l-7.

    Article  Google Scholar 

  87. Hohnloser S, Verrier RL, Lown B. Influence of beta-2adrenoceptor on cardiac electrophysiologic properties and serum potassium concentration in the anesthezied dog.Am Heart J 1987;113:1066–1070.

    Article  PubMed  CAS  Google Scholar 

  88. Hohnloser S, Weirich J, Antoni H. Effects of mexiletine on steady-state characteristics and recovery kinetics of Vmax and conduction velocity in the guinea pig myocardium.J Cardiovasc Pharmacol 1982;4:232–239.

    Article  PubMed  CAS  Google Scholar 

  89. Holt DW, Tucker GT, Jackson PR. Amiodarone pharmacokinetics.Am Heart J 1983;106:840–847.

    Article  PubMed  CAS  Google Scholar 

  90. Hondeghem LM. Effects of lidocaine, phenytoin and quinidine on the ischemic canine myocardium.J Electrocardiol 1986;9:203–210.

    Article  Google Scholar 

  91. Hondeghem LM. Interaction of class I drugs with the cardiac sodium channel. In: Vaughan Williams, EM, ed.Antiarrhythmic drugs. Springer Verlag, 1989:158.

  92. Hondeghen LM, Grant AD, Jensen RA. Antiarrhythmic drug action: Selective depression of hypoxic cardiac cells.Am Heart J 1974;87:602–605.

    Article  Google Scholar 

  93. Hondeghem LM, Katzung BG. Antiarrhythmic agents: The modulated receptor mechanism of action of sodium and calcium channel-blocking drugs.Ann Rev Pharmacol Toxicol 1984;24:387–423.

    Article  CAS  Google Scholar 

  94. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go.Circulation 1990;81:686–690.

    PubMed  CAS  Google Scholar 

  95. Hume RJ. Properties of myocardial potassium channels and their pharmacological modulation. In: Hondeghem LM, ed.Molecular and cellular mechanisms of antiarrhythmic agents. Mount Kisco, NY: Futura Publishing, 1989: 113–131.

    Google Scholar 

  96. Hust MH, Hohnloser S, Nitsche K, Just H. Torsades de pointes und kammerflattern.Internist 1984;25:68–71.

    PubMed  CAS  Google Scholar 

  97. Ikeda N, Singh BN, Davis LD, Hauswirth O. Effects of flecainide on the electrophysiologic properties of isolated canine and rabbit myocardial fibers.J Am Coll Cardiol 1985;5:303–310.

    PubMed  CAS  Google Scholar 

  98. Inoue H, Toda I, Nozaki A, et al. Inhomogeneity of ventricular refractory period in canine heart with quinidineinduced long QT interval: A comparative study on effects of heart rate, isoprenaline, and lignocaine.Cardiovasc Res 1985;19:623–630.

    Article  PubMed  CAS  Google Scholar 

  99. Inoue H, Toda I, Nozaki A, et al. Effects of bretylium tosylate on inhomogeneity of refractoriness and ventricular fibrillation threshold in canine hearts with quinidineinduced long QT interval.Cardiovasc Res 1985;19:655–660.

    Article  PubMed  CAS  Google Scholar 

  100. Jackman WM, Zipes DP, Nacarelli GV, et al. Electrophysiology of oral encainide.Am J Cardiol 1980;49:1270–1275.

    Article  Google Scholar 

  101. Jenzer HR, Hagemeijer F. Quinidine syncope: Torsade de pointes with low quinidine plasma concentrations.Eur J Cardiol 1976;4:447–451.

    PubMed  CAS  Google Scholar 

  102. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the QT interval and sudden death.Am Heart J 1957;54:59–64.

    Article  PubMed  CAS  Google Scholar 

  103. Kamiya K, Venkatesh N, Singh BN. Acute and chronic effects of ketanserin on the electrophysiologic properties of isolated rabbit ventricular myocardium: Particular reference to repolarization.Am Heart J 1988;115:1222–1228.

    Article  PubMed  CAS  Google Scholar 

  104. Kane KA, Winslow E. Antidysrhythmic and electrophysiological effects of a new antianginal agent, bepridil.J Cardiovasc Pharmacol 1980;2:193–197.

    PubMed  CAS  Google Scholar 

  105. Kass RS. Delayed rectification is not calcium activated current in Purkinje fibres.Biophys J 1982;37:342–346.

    Google Scholar 

  106. Kato R, Yabek S, Ikeda N. Electrophysiologic effects of dextroand levo-isomers of sotalol on isolated cardiac muscle.J Am Coll Cardiol 1986;7:116–123.

    PubMed  CAS  Google Scholar 

  107. Kay GN, Plumb VJ, Arciniegas JG, et al. Torsade de pointes: The long-short initiating sequence and other clinical features: Observations in 32 patients.J Am Coll Cardiol 1983;14:806–817.

    Google Scholar 

  108. Kemper HA. Thioridazine induced torsades de pointes. Successful therapy with isoproterenol.JAMA 1983;249: 2931–2934.

    Article  PubMed  CAS  Google Scholar 

  109. Keren A, Tzivoni D, Gavish D. Etiology, warning signs and therapy of torsade de pointes: A study of 10 patients.Circulation 1981;64:1167–1174.

    PubMed  CAS  Google Scholar 

  110. Keren A. Atypical ventricular tachycardia (torsades de pointes) introduced by amiodarone.Chest 1982;81:384.

    Article  PubMed  CAS  Google Scholar 

  111. Keren G, Tepper D, Butler B, et al. Studies on the possible mechanisms of lidoflazine arrhythmogenicity.J Am Coll Cardiol 1984;4:742–747.

    PubMed  CAS  Google Scholar 

  112. Kiss Z, Fazekas T. Disturbances in cardiac cycle after organophosphor intoxication.Orv Hetil 1978;119:1905–1908.

    PubMed  CAS  Google Scholar 

  113. Kiss Z, Fazekas T. Arrhythmias in organophosphate poisonings.Acta Cardiol 1979;34:3223–3230.

    Google Scholar 

  114. Kiss Z, Fazekas T. Organophosphates and torsade de pointes ventricular tachycardia.J Roy Soc Med 1983;76: 984–985.

    CAS  PubMed  Google Scholar 

  115. Klinnert U, Blenn B, Hofer HG, Saager TH. Kammerflimmern unter chinidintherapie (“chinidinsynkopen”).Therapiewoche 1978;28:398–406.

    Google Scholar 

  116. Kontopoulos A, Filindris A, Manoudis F, Metaxias P. Sotalol-induced torsade de pointes.Postgrad Med J 1981; 57:321–323.

    Article  PubMed  CAS  Google Scholar 

  117. Krapf R, Gertsch M. Torsade des pointes induced by sotalol despite therapeutic concentrations.Br Med J 1985;250: 1784–1785.

    Google Scholar 

  118. Kuck KH, Kinze KR, Roewer N. Bleinfeld W. Sotalolinduced torsade de pointes.Am Heart J 1984;107:179–180.

    Article  PubMed  CAS  Google Scholar 

  119. Kuo CS, Munakata K, Reddy CP, Surawicz. Characteristics and possible mechanisms of ventricular arrhythmia dependent on the dispersion of action potential durations.Circulation 1983;67:1356–1367.

    PubMed  CAS  Google Scholar 

  120. Kupersmith J, Hoff P, Duo GS. In vitro characteristics of repolarization abnormality—a possible cause of arrhythmias.J Electrocardiol 1986;19:361–369.

    PubMed  CAS  Google Scholar 

  121. Laakso M, Pertikainen PH, Lampainen E. Sotalol, prolonged Q-T interval and ventricular tachyarrhythmias.Ann Clin Res 1981;13:439–440.

    PubMed  CAS  Google Scholar 

  122. Laakso M, Pentikainen P, Pyörala K. Sotalol and the QTc interval. 1981;2:1168.

    CAS  Google Scholar 

  123. Laakso M, Pentikainen PJ, Pyörola K, Neuvonen PJ. Prolongation of the QT-interval caused by sotalol-possible association with ventricular tachyarrhythmias.Eur Heart J 1981;2:353–358.

    PubMed  CAS  Google Scholar 

  124. Labrid G, Leinot M, Beaughard M, et al. Comparative antidysrhythmic profile of bepridil, amiodarone and disopyramide in the guinea pig and dog.Arch Int Pharmacodyn Ther 1981;249:87–97.

    PubMed  CAS  Google Scholar 

  125. Lang KF, Schuster HP, Knolle J, et al. Arrhythmien bei alkylphosphatvergiftungen.Verh Dtsch Ges Innere Med 1970;76:614–618.

    Google Scholar 

  126. Lau CP, Ward DE. QT hysteresis: The effect of an abrupt change in pacing rate. In: Butrous GS, Schwartz P, eds.Clinical aspects of ventricular repolarization. London, Farrand Press, 1989:175.

    Google Scholar 

  127. Leclercq JF, Rural S, Valere PE. Bepridil et torsade de pointes.Arch Mal Coeur 1983;3:341–348.

    Google Scholar 

  128. Lepeschkin E, Surawicz B. The duration of the Q-U interval and its component in electrocardiograms of normal persons.Am Heart J 1953;46:9–20.

    Article  PubMed  CAS  Google Scholar 

  129. Levine JH, Spear JF, Guarnieri T, et al. Cesium chlorideinduced long QT syndrome: Demonstration of afterdepolarizations and triggered activity in vivo.Circulation 1985; 72(5):1092–1103.

    PubMed  CAS  Google Scholar 

  130. Levy MN. Neural control of cardiac rhythm and contraction. In: Rosen MR, Hoffman BF, eds.Cardiac therapy. Boston: Martinus Nijhoff Publishers, 1983:73.

    Google Scholar 

  131. Liozon F, Goudoud JC, Castel JP, et al. Torsades de pointes et arrhythmies ventriculaires graves par administration parentérale de vincamine.Arch Mal Coeur 1979; 73(3):298–304.

    Google Scholar 

  132. List WFM. Succinylcholine-induced cardiac arrhythmias.Anesth Analg Curr Res 1971;50:361–367.

    CAS  Google Scholar 

  133. Lo KS, Gantz KB, Stetson PL, et al. Disopyramideinduced ventricular tachycardia.Arch Intern Med 1980; 140:413–414.

    Article  PubMed  CAS  Google Scholar 

  134. Lown B, Graboys TB. Management of patients with malignant ventricular arrhythmias.Am J Cardiol 1977;39: 910–918.

    Article  PubMed  CAS  Google Scholar 

  135. Ludomirsky A, Klein HO, Sarelli P. Q-T prolongation and polymorhous (“torsade de pointes”) ventricular arrhythmias associated with organophosphorus insecticide poisoning.Am J Cardiol 1982;49:1654–1658.

    Article  PubMed  CAS  Google Scholar 

  136. Luzhnikov EA, Savina AS, Shepelev M. On the pathogenesis of cardiac rhythm and conductivity disorders in cases of acute insecticide poisonings.Kardiologiya (U.S.S.R.) 1975;15:126–129.

    CAS  Google Scholar 

  137. Manouvrier J, Sagot M, Caron C, et al. Nine cases of torsade de pointes with bepridil administration.Am Heart J 1986;111:1005–1008.

    Article  PubMed  CAS  Google Scholar 

  138. Narcys FI. Drug interactions with class III antiarrhythmic agents. In: Singh BN, ed.Control of cardiac arrhythmias by lenthening repolarization. Mount Kisco, NY: Futura Publishing Company, 1989:543.

    Google Scholar 

  139. Mason JW, Hondeghem LM: Quinidine.Ann NY Acad Sci 1984;432:162–168.

    Article  PubMed  CAS  Google Scholar 

  140. Mason JW, Hondeghem LM, Katzung BG. Block of inactivated sodium channels and of depolarization-induced automaticity in guinea-pig papillary muscle by amiodarone.Circ Res 1984;55:277–285.

    CAS  Google Scholar 

  141. Mattioni TA, Zheutlin TA, Dunnington C, Kehoe FR. The proarrhythmic effects of amiodarone.Prog Cardiovasc Dis 1989;6:439–446.

    Article  Google Scholar 

  142. McComb JM, Logan KR, Khan MM, et al. Amiodarone induced ventricular fibrillation.Eur J Cardiol 1980;11: 381–385.

    PubMed  CAS  Google Scholar 

  143. McComb J, Campbell NPS, Cleland J. Recurrent ventricular tachycardia associated with QT prolongation after mitral valve replacement and its association with intravenous administration of erythromycin.Am J Cardiol 1984;54: 922–923.

    Article  PubMed  CAS  Google Scholar 

  144. McKibben JK, Pocock WA, Barlow JB, et al. Sotalol, hypokalemia, syncope and torsade de pointes.Br Heart Jr 1984;51:157–162.

    Article  Google Scholar 

  145. Meanock CJ, Noble MIM. A case of prenylamine toxicity showing torsade de pointes phenomenon in sinus rhythm?Postgrad Med J 1981;57:381–384.

    Article  PubMed  CAS  Google Scholar 

  146. Mehta D, Warwick GL, Goldberg MJ. QT prolongation after ampicillin anaphylaxis.Br Heart J 1986;55:308–310.

    Article  PubMed  CAS  Google Scholar 

  147. Meltzer RS, Robert EW, McMorrow M, Martin RP. Atypical ventricular tachycardia as a manifestation of disopyramide toxicity.Am J Cardiol 1978;42:1049–1053.

    Article  PubMed  CAS  Google Scholar 

  148. Mettauer B, Rouleau JL, Burgess JH. Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure.Am Heart J 1985;109:840–848.

    Article  PubMed  CAS  Google Scholar 

  149. Minderjahn KP, Linnartz G, Münch H, Larbig DT. Sotalol induziertes long QT-syndrom mit malignen ventrikulären rhythmusstörungen (torsades de pointes) bericht über 2 fälle.Intensivmed 1986;23:113–115.

    Google Scholar 

  150. Mirro MJ, Manalan AS, Bailey JC, et al. Anticholinergic effects of disopyramide and quinidine on guinea pig myocardium: Mediation by direct mussscarinic receptor blockage.Cir Res 1989;47:855–865.

    Google Scholar 

  151. Mirvis DM. Spatial variation of QT intervals in normal persons and patients with acute myocardial infarction.J Am Coll Cardiol 1985;5:625–631.

    Article  PubMed  CAS  Google Scholar 

  152. Miura DS, Rosen MR. New directions in the development of antiarrhythmic drugs.J Clin Pharm 1984;24:333–341.

    CAS  Google Scholar 

  153. Moeschlin S.Klinik und Therapie der Vergiftungen. Stuttgart: Georg Thieme Verlag, 1986.

    Google Scholar 

  154. Montagna M, Groppi A. Fatal sotalol poisoning.Arch Toxicol 43:221–226.

  155. Morganroth J. Risk factors for the development of proarrhythmic events.Am J Cardiol 1987;59:32E-37E.

    Article  PubMed  CAS  Google Scholar 

  156. Moss AJ, Schwartz PJ. Delayed repolarization (QT or QTU prolongation) and malignant ventricular arrhythmias.Mod Cone Cardiovasc Dis 1982;51:85–90.

    CAS  Google Scholar 

  157. Muhiddin K, Nathan AW, Hellistrand KJ, et al. Ventricular tachycardia associated with flecainide.Lancet 1983;2: 1220–1221.

    Google Scholar 

  158. Naccarelli GV, Rinkenberger RL, Dougherty AH, et al. Pharmacologic therapy of arrhythmias.Hosp Prac 1983; 183–189.

  159. Nadamanee K, Hendrickson J, Kannan R, Singh BN. Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening arrhythmias.Am Heart J 1982;103:950–959.

    Article  Google Scholar 

  160. Nademanee K, Lockhart E, Pruitt C, Singh BN. Cardiac electrophysiologic effects of ketanserin in humans.J Cardiovasc Pharmacol 1987;10:S81-S85.

    Article  PubMed  Google Scholar 

  161. Nathan W, Hellstrand KJ, Bextan RS. Electrophysiological effects of sotalol—Just another beta-blocker?Br Heart J 1982;47:515–532.

    Article  PubMed  CAS  Google Scholar 

  162. Nawrath H, Ten Eick RE, McDonald TF. On the mechanism underlying the action of D600 in slow inward current and tension in mammalian myocardium.Circ Res 1977;40: 408–414.

    PubMed  CAS  Google Scholar 

  163. Nestico PF, Morganroth J, Horowitz LN. New antiarrhythmic drugs.Drugs 1989;35:286–300.

    Article  Google Scholar 

  164. Neuvonen PJ, Elonen E, Tarasanen L. Sotalol intoxication, two patients with concentration-effect relationships.Acta Pharmacol Toxicol 1979;45:52–57.

    CAS  Google Scholar 

  165. Neuvonen PJ, Elonen E, Vuorenmaa T, Laakso M. Prolonged Q-T interval and ventricular tachyarrhythmics: Common features of sotalol intoxication.Eur J Clin Pharmacol 1981;20:85–89.

    Article  PubMed  CAS  Google Scholar 

  166. Nguyen PT, Scheinman MM, Seger J. Polymorphous ventricular tachycardia: Clinical characterization, therapy, and the QT interval.Circulation 1986;74:340–349.

    PubMed  CAS  Google Scholar 

  167. Nicholson WJ, Martin CE, Gracey JG, Knoch HR. Disopyramide-induced ventricular fibrillation.Am J Cardiol 1979;43:1053–1055.

    Article  PubMed  CAS  Google Scholar 

  168. Noble D, Tsien RW. Outward membrane currents activated in the plateau range of potentials in cardiac Purkinje fibers.J Physiol 1969;200:205–231.

    PubMed  CAS  Google Scholar 

  169. Noma A, Tohru S. Properties of adenosine-triphosphateregulated potassium channels in guinea-pig ventricular cells.J Physiol 1985;363:463.

    PubMed  CAS  Google Scholar 

  170. Normand JP, Kahn JC, Mialet. Torsades de pointes induites ou a favorisees par la prenylamine. A propis de 4 observations.Ann Cardiol Angiol 1974;23:527–533.

    CAS  Google Scholar 

  171. Oakley D, Jennings K, Puritz R, et al. The effect of prenylamine of the QT interval of the resting electrocardiogram in patients with angina pectoris.Postgrad Med J 1980;56: 753–756.

    Article  PubMed  CAS  Google Scholar 

  172. Olshansky B, Martins J, Hunt S. N-acetyl procainamide causing torsade de pointes.Am J Cardiol 1982;50: 1439–1441.

    Article  PubMed  CAS  Google Scholar 

  173. Olsson SB. Class III antiarrhythmic action. In: Vaughan Williams, EM, ed.Antiarrhythmic drugs. Springer Verlag, 1989:323.

  174. Pantano JA. Reply to the letter “Arrhythmias and QT interval in athletes.”Am Heart J 1984;107:608.

    Article  Google Scholar 

  175. Platou ES, Refsum H. Class III antiarrhythmic action in experimental atrial fibrillation and flutter in dogs.J Cardiovasc Pharmacol 1982;4:839–844.

    Article  PubMed  CAS  Google Scholar 

  176. Podrid PJ. Can antiarrhythmic drugs cause arrhythmia?J Clin Pharmacol 1984;24:313–318.

    PubMed  CAS  Google Scholar 

  177. Podrid PJ. Aggravation of ventricular arrhythmia. A drug-induced complication.Drugs 1985;29(4):33–44.

    Article  PubMed  Google Scholar 

  178. Polster P, Broekhuysen J. The adrenergic antagonism of amiodarone.Biochem Pharmacol 1976;25:131–134.

    Article  PubMed  CAS  Google Scholar 

  179. Prystowski EN. Electrophysiologic and antiarrhythmic properties of bepridil.Am J Cardiol 1985;55:59c-62c.

    Article  Google Scholar 

  180. Puritz R, Henderson MA, Baker SN, Chamberlain DA. Ventricular arrhythmias claused by prenylamine.Br Med J 1977;2:608–609.

    Article  PubMed  CAS  Google Scholar 

  181. Quiret JC, Bens JL, Courbet MT, et al. Les torsades de pointes: Un modèle de pathologic iatrogène.Ann Inter Med 1976;127:615–621.

    CAS  Google Scholar 

  182. Rainier-Pope CR, Chrire V, Beck W, Barnard CN. The treatment of quinidine-induced ventricular fibrillation by closed-chest resuscitation and external defibrillationAm Heart J 1962;63(5):582–589.

    Article  Google Scholar 

  183. Reynolds EW, Vander Ark CR. Quinidine syncope and the delayed repolarization syndromes.Mod Cone Cardiovasc Dis 1976;45:117–122.

    CAS  Google Scholar 

  184. Roden DM, Baiser JR, Bennett PB. Modulation of cardiac potassium currents by antiarrhythmic drugs. Focus on the cardiac delayed rectifier. In: Hondeghem IM, ed.Molecular and cellular mechanisms of antiarrhythmic agents. Mount Kisco, NY: Futura Publishing, 1989:132–154.

    Google Scholar 

  185. Roden DM. Arrhythmogenic potential of Class III antiarrhythmic agents: Comparison with Class I agents. In:Control of cardiac arrhythmias by lengthening repolarization. Singh BN, ed. Mount Kisco, NY: Futura Publishing Company, 1988:559–577.

    Google Scholar 

  186. Roden DM, Hoffman BF. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length.Circ Res 1985;56:857–867.

    PubMed  CAS  Google Scholar 

  187. Roizen MF, Stevens WC. Multiform ventricular tachycardia due to the interaction of aminophylline and halothane.Anaes Analg 1978;57:738–741.

    CAS  Google Scholar 

  188. Rosen MR, Gelband H, Merker C. Effects of procainamide on the electrophysiologic properties of the canine ventricular conducting system.J Pharmacol Exp Ther 1973;185: 438–444.

    PubMed  CAS  Google Scholar 

  189. Saal AK, Werner JA, Greene HL, Effect of amiodarone on serum quinidine and procainamide levels.Am J Cardiol 1984;53:1264–1267.

    Article  PubMed  CAS  Google Scholar 

  190. Sarma JSM, Venkataraman K, Katz D. The concept of corrected QT interval: Pitfalls and alternatives. In: Butrous GS, Schwartz P, ed.Clinical aspects of ventricular repolarization. London: Farrand Press, 1989:31.

    Google Scholar 

  191. Sartori M, Peratt CM, Young JB. Torsades de pointes, malignant cardiac arrhythmia induced by amantadine poisoning.Am J Med 1984;77:388–391.

    Article  PubMed  CAS  Google Scholar 

  192. Sasyniuk BI, Valois M, Toy W. Recent advances in understanding the mechanisms of drug-induced torsades de pointes arrhythmias.Am J Cardiol 1989;64(20):29J-32J.

    Article  PubMed  CAS  Google Scholar 

  193. Scagliotti D, Strasberg B, Hai HA, et al. Aprindineinduced polymorphous ventricular tachycardia.Am J Cardiol 1982;49:1297–1300.

    Article  PubMed  CAS  Google Scholar 

  194. Schlepper M, Derro R. Antifibrillatory effects of lidoflazine, a clinical study.Arzneimittelforsch 1972;22: 923–928.

    PubMed  CAS  Google Scholar 

  195. Schlepper M, Neuss H. Changes of refractory periods in the AV conduction system induced by antiarrhythmic drugs. A study using His bundle recordings.Acta Cardiol (Brussels) 1974;18(Suppl):269

    Google Scholar 

  196. Schwartz P, Wolf S. QT interval prolongation as a predictor of sudden death in patients with myocardial infarction.Circulation 1978;57:1074–1077.

    PubMed  CAS  Google Scholar 

  197. Schweitzer P, Mark H. Delayed repolarization syndrome.Am J Med 1978;75:393–401.

    Article  Google Scholar 

  198. Sclarovsky S, Damian A, Krakoff O, et al. Polymorphous ventricular tachycardia in patients receiving prenylamine.Harefuah 1979;96:227–233.

    Google Scholar 

  199. Sclarovsky S, Lewin RF, Kracoff O, et al. Amiodaroneinduced polymorphous ventricular tachycardia.Am Heart J 1983;105(I)6–12.

    Article  PubMed  CAS  Google Scholar 

  200. Sclarovsky S, Strasberg B, Lewin RF, Agmon J. Polymorphous ventricular tachycardia: Clinical features and treatment.Am J Cardiol 1979;339-344.

  201. Segantini A, Varisco T, Monza E, et al. QT prolongation and sudden infant death syndrome (SIDS). In: Butrous GS, Schwartz P, eds.Clinical aspects of ventricular repolarization. London: Farrand Press, 1989:415–419.

    Google Scholar 

  202. Seipel L, Abendroth RR, Breithard TG. Electrophysiological effects of flecainide (R-818) in man.Circulation 1980; 62(Part III):153.

    Google Scholar 

  203. Selzer A, Wray HW. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias.Circulation 1964;30:17.

    PubMed  CAS  Google Scholar 

  204. Shea P, Lal R, Kim SS. Flecainide and amiodarone interaction.J Am Coll Cardiol 1986;7:1127–1130.

    Article  PubMed  CAS  Google Scholar 

  205. Singh B. Amiodarone: Historical development and pharmacologic profile.Am Heart J 1983;106:788–797.

    Article  PubMed  CAS  Google Scholar 

  206. Singh BN.Control of cardiac arrhythmias by lengthening repolarization. Mount Kisco, NY: Futura Publishing, 1988.

    Google Scholar 

  207. Singh BN. A study of the pharmacological actions of certain drugs and hormones with a particular reference to cardiac muscle. D. Phil. Thesis, England, University of Oxford, 1971.

    Google Scholar 

  208. Singh BN. Amiodarone: Electropharmacologic properties. In: Vaughan Williams, EH, ed.Antiarrhythmic drugs. Springer Verlag, 1989:335–364

  209. Singh BN. When is QT prolongation antiarrhythmic and when is it proarrhythmic?Am J Cardiol 1989;63:867–869.

    Article  PubMed  CAS  Google Scholar 

  210. Singh BN, Nademanee K. Sotalol: A beta blocker with unique antiarrhythmic properties.Am Heart J 1987;114: 1040–1050.

    Article  PubMed  CAS  Google Scholar 

  211. Singh BN, Nadamanee K, Feld G. Comparative electrophysiologic profiles of calcium antagonists with particular reference to bepridil hydrochloride.Am J Cardiol 1985; 55:14–19c.

    Article  CAS  Google Scholar 

  212. Soffer J, Dreifus LS, Michelson EL. Polymorphous ventricular tachycardia associated with normal and long Q-T intervals.Am J Cardiol 1982;49:2021–2029.

    Article  PubMed  CAS  Google Scholar 

  213. Somberg JC. Calcium channel blockers that prolong the QT interval.Am Heart J 1985;109(2):416–421.

    Article  PubMed  CAS  Google Scholar 

  214. Somberg JC. Clinical use of class Ic antiarrhythmic agents. In: Vaughan Williams, EM, ed.Antiarrhythmic drugs. Springer Verlag, 1989;235-265.

  215. Somberg J, Tepper D, Wynn J. Prolonged repolarization: A historical perspective.Am Heart J 1985;109(2):395–398.

    Article  PubMed  CAS  Google Scholar 

  216. Southworth W, Friday KJ, Ruffy R. Possible amiodaroneapridine interaction.Am Heart J 1982;104:323.

    Article  PubMed  CAS  Google Scholar 

  217. Späth G.Vergiftungen und akute Arzneimitttelüberdosierungen. Verlag Gerhard Witzstrock Baden-Baden Köln New York: Verlag de Gruyter, 1978.

    Google Scholar 

  218. Späth G. Torsade de pointes. Überreuter Wissenschaftsverlag, Wien, 1988.

    Google Scholar 

  219. Steinberg ML, Lindstrom TD, Fasola AF. Clofilium. In: Scrabine A, ed.New York Drugs Annual: Cardiovasc Drugs, Vol. 2. New York: Raven Press, 1984:103–123.

    Google Scholar 

  220. Storstein O. Syncope and sudden death as a side effect of treatment with antiarrhythmic drugs. In: Sandoe E, Flensted-Jensen E, Olesen KH, eds:Symposium on cardiac arrhythmias. Sweden, AB Astra 1970:505.

    Google Scholar 

  221. Strassberg B, Coelho A, Welche W, et al. eds: Doxepin induced torsade de pointes.Pace 1982;5:873.

    Google Scholar 

  222. Strassberg B, Scalarovsky S, Erberg A, et al. Procainamide-induced polymorphic ventricular tachycardia.Am J Cardiol 1981;47:1309–1314.

    Article  Google Scholar 

  223. Strauss HC, Bigger JT, Hoffman BF. Electrophysiological and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue.Circ Res 1970;26:661–664.

    PubMed  CAS  Google Scholar 

  224. Surawicz B. The QT interval and cardiac arrhythmias.Ann Rev Med 1987;38:81–90.

    Article  PubMed  CAS  Google Scholar 

  225. Surawicz B. Mechanisms of QT prolongation and arrhythmias. In: Butrous GS, Schwartz PJ, eds.Clinical aspects of ventricular repolarization. London: Farrand Press, 1989: 227–43.

    Google Scholar 

  226. Surawicz B, Knoebel SB. Long QT: Good, bad or indifferent.J Am Coll Cardiol 1984;4:398–413.

    Article  PubMed  CAS  Google Scholar 

  227. Surawicz B. R on T phenomenon: Dangerous and harmless.J Appl Cardiol 1986;1:39–43.

    Google Scholar 

  228. Swiryn S, Kim SS. Quinidine-induced syncope.Arch Intern Med 1983;143:314–316.

    Article  PubMed  CAS  Google Scholar 

  229. Takanaka C, Singh BN. Barium-induced non-driven action potentials as a model of triggered automaticity and early afterdepolarizations: Differing effects of amiodarone, lidocaine and quinidine and significance of slow channelactivity,.J Am Coll Cardiol 1990, in press.

  230. Tartini R, Kappenberger L, Steinbrunn W. Dangerous interaction between amiodarone and quinidine.Lancet 1982; 1327–1329.

  231. Terry G, Vellani CW, Higgins MR. Bretylium tosylate in treating refractory ventricular arrhythmias complicating myocardial infarction.Br Heart J 1970;32:21–25.

    Article  PubMed  CAS  Google Scholar 

  232. Vaughan William EM. QT and action potential duration.Br Heart J 1982;47:513–514.

    Article  Google Scholar 

  233. Vaughan William EM: Disopyramide.Ann NY Acad Sci 1984;432:189–200.

    Article  Google Scholar 

  234. Vaughan Williams EM. The effect of changes in extracellular potassium concentration on the intracellular potential record. JPhysiol 1959;146:411–427.

    Google Scholar 

  235. Vaughan Williams EM. Cardiac electrophysiology. In: Vaughan Williams, EM, ed.Antiarrhythmic drugs. Springer Verlag, 1989:1–39.

  236. Vaughan Williams, EM. Significance of action potential duration and the QT interval in the origin and treatment of ventricular arrhythmias. In: Butrous GS, Schwartz P, eds.Clinical aspects of ventricular repolarization. London: Farrand Press, 1989:243–251.

    Google Scholar 

  237. Vaughan Williams EM: A classification of antiarrhythmic actions reassessed after a decade of new drugs.J Clin Pharmacol 1984;24:129–147.

    Google Scholar 

  238. Veglia L, Scandifflio T, Guerricchio G. Torsioni di punta e amiodarone.G Ital Cardiol 1978;8:1025–1028.

    PubMed  CAS  Google Scholar 

  239. Verdonck F, Vereecke J, Vlengels A: Electrophysiological effects of aprindine on isolated heart preparations.Eur J Pharmacol 1974;26:338–347.

    Article  PubMed  CAS  Google Scholar 

  240. Ward DE. Is it appropriate to correct the QT interval for heart rate. In: Butrous GS, Schwartz PJ, eds.Clinical aspects of ventricular repolarization. London: Farrand Press, 1989:17–31.

    Google Scholar 

  241. Ward DE, Camm AJ, Spurell RAJ. The acute electrophysiological effects of intravenous sotalol hydrochloride.Clin Cardiol 1979;2:185–190.

    PubMed  CAS  Google Scholar 

  242. Winkle RA, Peters F, Kates RE, et al. Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with ventricular arrhythmias.Circulation 1981;6:290–296.

    Google Scholar 

  243. Wit AL: Cellular electrophysiologic mechanism of cardiac arrhythmias.Ann NY Acad Sci 1984;432:1–16.

    Article  PubMed  CAS  Google Scholar 

  244. Wit AL, Steiner C, Damato AN. Electrophysiologic effects of bretylium tosylate on single fibers of the canine specialized conducting system and ventricle.J Pharmacol Exp Ther 1970;173:344–356.

    PubMed  CAS  Google Scholar 

  245. Yamaguchi I, Sing BN, Mandel WJ. Electrophysiological actions of mexiletine on isolated rabbit atria and canine ventricular muscle and Purkinje fibers.Cardiovasc Res 1979;13:288–296.

    Article  PubMed  CAS  Google Scholar 

  246. Yoon MS, Han J, Dersham GH, Jones SA. Effects of thioridazine (Mellaril) on ventricualr electrophysiologic properties.Am J Cardiol 1979;43:1155–1158.

    Article  PubMed  CAS  Google Scholar 

  247. Young JB, Vandermolen LA, Pratt CM. Torsades de pointes: An unusual manifestation of chloral hydrate poisoning.Am Heart J 1986;112:181–184.

    Article  PubMed  CAS  Google Scholar 

  248. Zehender M, Geibel A, Henning B, et al. Bepridilelektrophsysiologische eigenschaften eines neuen kalziumantagonisten mit antiarrhythmischer Wirksamkeit.Z Kardiol 1988;77:93–98.

    PubMed  CAS  Google Scholar 

  249. Zehender M, Meinertz T, Hohnloser S, et al. the Multicenter Ketanserin Research Group. Incidence and clinical relevance of QT prolongation caused by the selective serotonin antagonist ketanserin.Am J Cardiol 1989; 63:826–832.

    Article  PubMed  CAS  Google Scholar 

  250. Zehender M, Meinertz T, Keul J, Just H. ECG variants and cardiac arrhythmias in athletes: Clinical relevance and prognostic importance.Am Heart J. 1990;119(6):1378–1391.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zehender, M., Hohnloser, S. & Just, H. QT-Interval prolonging drugs: Mechanisms and clinical relevance of their arrhythmogenic hazards. Cardiovasc Drug Ther 5, 515–530 (1991). https://doi.org/10.1007/BF03029779

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03029779

Key Words

Navigation